Ken Griffin Reata Pharmaceuticals Inc Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$79.22 - $105.37 $42.7 Million - $56.8 Million	539,322 Added 1674.55%	571,529 $58.3 Million
Q1 2023 May 15, 2023	SELL	$30.85 - $93.17 $1.31 Million - $3.95 Million	-42,429 Reduced 56.85%	32,207 $2.93 Million
Q4 2022 Feb 14, 2023	SELL	$22.15 - $42.11 $1.93 Million - $3.67 Million	-87,179 Reduced 53.88%	74,636 $2.84 Million
Q3 2022 Nov 14, 2022	SELL	$19.41 - $36.49 $1.29 Million - $2.43 Million	-66,688 Reduced 29.18%	161,815 $4.07 Million
Q2 2022 Aug 15, 2022	BUY	$20.71 - $36.5 $2.06 Million - $3.64 Million	99,660 Added 77.35%	228,503 $6.94 Million
Q1 2022 May 16, 2022	BUY	$24.12 - $39.6 $1.65 Million - $2.71 Million	68,422 Added 113.24%	128,843 $4.22 Million
Q4 2021 Feb 14, 2022	BUY	$25.61 - $110.96 $1.39 Million - $6.02 Million	54,228 Added 875.63%	60,421 $1.59 Million
Q3 2021 Nov 15, 2021	SELL	$100.0 - $143.02 $1.5 Million - $2.15 Million	-15,036 Reduced 70.83%	6,193 $623,000
Q1 2021 May 17, 2021	SELL	$94.25 - $132.81 $214,324 - $302,009	-2,274 Reduced 9.68%	21,229 $2.12 Million
Q4 2020 Feb 16, 2021	SELL	$102.03 - $184.62 $1.06 Million - $1.91 Million	-10,369 Reduced 30.61%	23,503 $2.91 Million
Q3 2020 Nov 16, 2020	SELL	$93.53 - $163.34 $1.86 Million - $3.25 Million	-19,908 Reduced 37.02%	33,872 $3.3 Million
Q2 2020 Aug 14, 2020	SELL	$126.3 - $176.56 $2.8 Million - $3.91 Million	-22,141 Reduced 29.16%	53,780 $8.39 Million
Q1 2020 May 15, 2020	BUY	$124.16 - $247.74 $5.21 Million - $10.4 Million	41,951 Added 123.49%	75,921 $11 Million
Q4 2019 Feb 14, 2020	BUY	$74.57 - $217.92 $1.54 Million - $4.49 Million	20,598 Added 154.04%	33,970 $6.95 Million
Q3 2019 Nov 14, 2019	BUY	$71.26 - $95.75 $392,143 - $526,912	5,503 Added 69.93%	13,372 $1.07 Million
Q2 2019 Aug 14, 2019	SELL	$77.72 - $94.35 $530,672 - $644,221	-6,828 Reduced 46.46%	7,869 $742,000
Q1 2019 May 15, 2019	BUY	$51.9 - $101.79 $480,957 - $943,287	9,267 Added 170.66%	14,697 $0
Q4 2018 Feb 14, 2019	SELL	$48.76 - $76.44 $1.69 Million - $2.65 Million	-34,732 Reduced 86.48%	5,430 $304,000
Q3 2018 Nov 13, 2018	BUY	$35.64 - $92.06 $1.14 Million - $2.93 Million	31,880 Added 384.93%	40,162 $0
Q2 2018 Aug 10, 2018	SELL	$19.94 - $40.96 $318,441 - $654,131	-15,970 Reduced 65.85%	8,282 $0
Q1 2018 May 11, 2018	BUY	$20.0 - $30.19 $485,040 - $732,167	24,252 New	24,252 $497,000
Q4 2017 Feb 09, 2018	SELL	$22.39 - $33.27 $184,314 - $273,878	-8,232 Closed	0 $0
Q3 2017 Nov 09, 2017	BUY	$26.29 - $31.88 $216,419 - $262,436	8,232	8,232 $256,000

Others Institutions Holding RETA

# of Institutions

Shares Held

62.7K

Call Options Held

Put Options Held

View Full List

About REATA PHARMACEUTICALS INC

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

More about RETA

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account